Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) Patient Assistance Program
Don’t let the high cost of brand subcutaneous anti-CD20 MS biologic disrupt your multiple sclerosis treatment. We help eligible patients access Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq subcutaneous injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) is FDA-approved for the same indications as original IV Ocrevus: relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease) and primary progressive multiple sclerosis (PPMS) in adults. Subcutaneous formulation co-formulated with rHuPH20 hyaluronidase enabling a rapid 10-minute SC injection alternative to hours-long IV.
- Without assistance, Ocrevus Zunovo costs commonly run approximately $35,000–$42,000 per dose (every 6 months — same dosing schedule as original IV).
- Through AffordMyPrescriptions, qualifying patients can access Ocrevus Zunovo for a flat $69.95 per month.
- Same active drug as IV Ocrevus (ocrelizumab) — same efficacy and safety profile per OCARINA bridging studies. Other anti-CD20 MS therapies: Kesimpta (ofatumumab — monthly SC self-injection), Briumvi (ublituximab — IV every 6 months). Other high-efficacy DMTs: natalizumab (Tysabri), alemtuzumab (Lemtrada), cladribine tablets (Mavenclad). Moderate-efficacy DMTs (mostly oral): fingolimod (Gilenya generic), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory), dimethyl fumarate (Tecfidera generic), teriflunomide (Aubagio generic). Platform injectable: interferon-beta (generic), glatiramer acetate (generic).
What is Ocrevus Zunovo Prescription Assistance Program?
The Ocrevus Zunovo Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Ocrevus Zunovo (used for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in subcutaneous injection format) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, neurology coordination, hepatitis B and tuberculosis screening documentation, and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Ocrevus Zunovo PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your neurologist for required documentation, follow up with the manufacturer’s program until approval, manage your twice-yearly SC injection schedule, and handle annual re-certification.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Ocrevus Zunovo enrollment — from the initial application through ongoing refills and re-enrollment — so you never face a gap in your multiple sclerosis treatment.
Pharmacy Price Comparison
- Without assistance, Ocrevus Zunovo costs tens of thousands of dollars per dose at MS treatment centers. Discount cards offer minimal relief at this price point, but a Patient Assistance Program can make this convenient SC MS biologic accessible if you qualify. The table below compares typical pricing to what you'd pay with our Ocrevus Zunovo advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Kesimpta (alt monthly SC) | ~$6,500/mo | Alt monthly SC anti-CD20 |
| Hospital infusion center | ~$40,000/dose | Save substantially |
| Community infusion center | ~$38,000/dose | Save substantially |
| Specialty pharmacy | ~$36,000/dose | Save substantially |
| 340B-eligible institution | ~$35,000/dose | Save substantially |
| Original IV Ocrevus (alt) | ~$38,000/dose | Same drug, IV route |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Ocrevus Zunovo — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Ocrevus Zunovo Prescription Program?
The Ocrevus Zunovo Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management. Our $69.95 per month covers full advocacy. Ocrevus Zunovo’s 10-minute SC injection substantially reduces chair time vs the hours-long IV original.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Ocrevus Zunovo assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Ocrevus Zunovo is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ocrevus Zunovo:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $35,000–$42,000/dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Ocrevus Zunovo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Ocrevus Zunovo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Ocrevus Zunovo:
Ocrevus Zunovo is subcutaneous ocrelizumab co-formulated with rHuPH20 hyaluronidase, enabling SC delivery of a large biologic volume — a 10-minute SC injection alternative to the hours-long IV original Ocrevus. Same anti-CD20 monoclonal antibody mechanism, same efficacy and safety profile, same twice-yearly dosing schedule — with convenience and reduced chair time for ocrelizumab-treated MS patients.
How It Works:
Multiple sclerosis is a chronic autoimmune demyelinating disease of the CNS with significant B-cell contribution to pathophysiology. B-cell depletion via anti-CD20 therapy effectively reduces MS disease activity in both relapsing forms and primary progressive MS. Ocrelizumab (the active drug in both IV Ocrevus and Ocrevus Zunovo) binds CD20 on B cells — selectively depleting circulating and tissue B cells through ADCC and CDC. The hyaluronidase in Ocrevus Zunovo temporarily degrades subcutaneous hyaluronic acid, enabling rapid SC delivery of the relatively large biologic volume. Same B-cell depletion, same efficacy, same dosing schedule (twice-yearly after loading) as the IV original.
Form and Use:
Ocrevus Zunovo SC injection in the abdomen. Initial loading: 920 mg SC on day 1 (single dose — different from the IV split-dose loading), then 920 mg SC every 6 months maintenance. Premedication with methylprednisolone (or equivalent) and an antihistamine before injection to reduce reactions. Periodic CBC, immunoglobulins, and infection monitoring. HBV and TB screening before initiation.
Generic Availability:
No biosimilar/generic. Original IV Ocrevus (same active drug, IV route, split-dose loading then twice-yearly IV). Other anti-CD20 MS therapies: Kesimpta (ofatumumab — monthly SC self-injection at home, also anti-CD20), Briumvi (ublituximab — IV every 6 months after loading). Other high-efficacy DMTs: natalizumab (Tysabri — anti-α4β7, monthly IV, PML risk), alemtuzumab (Lemtrada — anti-CD52), cladribine tablets (Mavenclad). Moderate-efficacy oral DMTs (generic available): fingolimod (Gilenya generic), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory), dimethyl fumarate (Tecfidera generic), diroximel fumarate (Vumerity), teriflunomide (Aubagio generic). Platform injectable: interferon-beta (generic), glatiramer acetate (Copaxone generic). Symptomatic management: dalfampridine (Ampyra generic), baclofen, bladder agents. For relapses: IV methylprednisolone (generic), plasmapheresis for refractory.
Warnings:
Same warnings as IV Ocrevus: infusion/injection reactions (premedicate, monitor), serious infections (bacterial, viral, fungal — including hepatitis B reactivation; mandatory HBV screening with antiviral prophylaxis if exposure history; TB screening; opportunistic infections; rare PML/JC virus reactivation), malignancy (increased breast cancer rate observed in trials — appropriate cancer screening), hypogammaglobulinemia (prolonged therapy — consider IVIG for recurrent infections), embryo-fetal toxicity. Other: cytopenias, fatigue, respiratory infections, skin and urinary tract infections, oral herpes, injection site reactions. Live vaccines contraindicated during therapy — update vaccines (recombinant zoster, COVID-19, flu, HBV) before starting if possible.
FAQ (Frequently Asked Questions)
How much does Ocrevus Zunovo cost without insurance?
$35,000–$42,000 per dose (every 6 months). Annual cost $70,000–$84,000 — same range as IV Ocrevus. Specialty pharmacy and Patient Assistance Programs are essential for most patients.
What is the difference between Ocrevus Zunovo and original IV Ocrevus?
Same active drug (ocrelizumab). Same efficacy and safety profile (per the OCARINA bridging trial). Same twice-yearly dosing schedule. Ocrevus Zunovo is a 10-minute SC injection; IV Ocrevus is an infusion over hours. Loading schedules differ — Zunovo uses a single 920 mg dose; IV uses split-dose 300+300 mg over 2 weeks. Both achieve the same B-cell depletion and clinical effect.
Why choose Ocrevus Zunovo over IV Ocrevus?
Substantially reduced chair time (10 minutes vs hours), often eliminates the need for an infusion center visit, more convenient scheduling, and easier logistics. Same drug, same efficacy, same safety. For patients with no clinical reason to prefer IV, Ocrevus Zunovo is generally more convenient.
Can I switch from IV Ocrevus to Ocrevus Zunovo?
Yes — switching at a maintenance dose is straightforward. Use 920 mg SC (Zunovo) instead of 600 mg IV at the next 6-month dose. Discuss with your neurologist.
Why is hepatitis B screening required before Ocrevus Zunovo?
B-cell-depleting therapy can reactivate hepatitis B in patients with prior exposure. Mandatory screening of HBsAg, anti-HBc, and anti-HBs before initiation. Antiviral prophylaxis with entecavir or tenofovir is appropriate if there is HBV exposure history. Same screening as IV Ocrevus.
Take Control of Your Medication Costs
Subcutaneous B-cell-depleting biologic therapy for relapsing or primary progressive MS should not be derailed by cost. Ocrevus Zunovo’s 10-minute SC injection offers significant convenience vs IV. Our advocacy team is ready to verify eligibility, complete the manufacturer application, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.